Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study assessing AUTO6-NG in patients with GD2 positive tumors including refractory/relapsed neuroblastoma

Next Previous
Trial Profile

Phase 1 study assessing AUTO6-NG in patients with GD2 positive tumors including refractory/relapsed neuroblastoma

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AUTO6NG (Primary)
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Acronyms MCARGD2

Most Recent Events

  • 05 May 2022 According to an Autolus media release, this trial is expected to begin in 2H 2022. First data expected in H2 2023.
  • 10 Mar 2022 According to an Autolus media release, the company expects to initiate this trial in mid-2022.
  • 05 Aug 2021 According to an Autolus media release, the company expects to initiate this trial in H1 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top